Imagine a future where a simple blood test after surgery could predict whether your cancer will return and guide your treatment decisions. That future is closer than you think, thanks to groundbreaking research on a biomarker called ctDNA. But here's where it gets controversial: could this test revolutionize rectal cancer care, or are we jumping the gun? Let’s dive into the GALAXY study, which sheds light on this fascinating yet complex topic.
The GALAXY study, part of the CIRCULATE Japan platform, tackled a straightforward yet critical question: Can ctDNA—a marker of molecular residual disease (MRD) detected in the blood after surgery—predict recurrence risk and identify patients who truly benefit from adjuvant chemotherapy (ACT) in stage II–III rectal cancer treated with upfront surgery? Most existing data on ctDNA in rectal cancer come from patients who received neoadjuvant therapy, complicating interpretation. This study, however, focused on a 'cleaner' clinical scenario: 250 patients with pathologic stage II–III rectal cancer who underwent curative-intent surgery, followed by postoperative ctDNA testing.
And this is the part most people miss: ctDNA was assessed using Signatera, a personalized assay that detects tumor-specific variants in the blood. Blood samples were collected at key postoperative intervals: 2–10 weeks (the MRD window), 3 months, 6 months, and beyond. The primary goal? To determine if ctDNA could stratify recurrence risk and predict ACT benefit, distinguishing patients who would thrive with chemotherapy from those who wouldn’t.
The results were striking. First, ctDNA status in the MRD window sharply divided patients into high- and low-risk groups. Only 14.2% of patients were ctDNA-positive at this stage, but their 12-month disease-free survival (DFS) was a mere 35.0%, compared to 89.5% in ctDNA-negative patients. This disparity persisted and intensified over time, with ctDNA-positive patients at 3 and 6 months facing significantly higher recurrence risks. During surveillance, ctDNA positivity conferred a staggering 25-fold higher risk of recurrence.
But here’s the real game-changer: ctDNA wasn’t just prognostic—it was predictive. ctDNA-negative patients saw no significant DFS benefit from ACT, while ctDNA-positive patients experienced a 72% reduction in recurrence risk with chemotherapy. This suggests ctDNA could be a powerful tool for personalized treatment, not just risk assessment.
The study also highlighted the importance of serial monitoring. Patients who converted from ctDNA-negative to positive faced markedly higher recurrence risks, underscoring the value of repeated testing. Interestingly, lung metastases were often ctDNA-negative early on, a finding that aligns with known biology but cautions against overinterpreting early negative results in high-risk contexts.
So, is ctDNA the future of rectal cancer care? The GALAXY study makes a compelling case, but it’s not without caveats. Treatment paradigms vary globally, and randomized trials are essential to validate these findings. Still, the potential for ctDNA-guided, personalized care is undeniable. What do you think? Is this the next big leap in oncology, or are we overestimating its impact? Let’s discuss in the comments!
